The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment
Authors:
- 1 October 2016
- journal article
- review article
- Published by Elsevier in Oral Oncology
- Vol. 61, 152-158
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Programmed Death Ligand 2 in Cancer-Induced Immune SuppressionJournal of Immunology Research, 2012
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysisBritish Journal of Cancer, 2011
- In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitorsCancer Immunology, Immunotherapy, 2010
- The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humansJournal of Experimental Medicine, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infectionJournal of Experimental Medicine, 2006
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004